文献速递前列腺癌

前列腺靶向穿刺活检是否提高高级别前列腺癌检出率或导致Will Rogers现象

Targeted biopsy of the prostate: does this result in improvement in detection of high-grade cancer or the occurrence of the Will Rogers phenomenon?
PubMed 文献 · BJU Int · 2019-06-02

该回顾性分析纳入107例经直肠超声引导系统非靶向穿刺确诊为Gleason 3+4的前列腺癌患者,随后行多参数MRI及MRI靶向经会阴穿刺活检。结果显示84例(78.5%)两方法均为Gleason 3+4,23例(22%)经靶向活检升级为更高风险疾病,差异显著(P=0.0006)。作者认为约五分之一患者从有利中危升级为不利中危或更差,对主动监测或根治性治疗决策有重要临床意义。

要点

  • 107例经直肠系统穿刺为Gleason 3+4患者中,84例(78.5%)靶向穿刺仍为3+4。
  • 19例(17.8%)升级为Gleason 4+3,3例(3.0%)升级为4+4,1例(1.0%)升级为4+5。
  • 23/107例(22%)基于靶向活检结果归为更高风险疾病,差异显著(P=0.0006)。

核心结论

  • 在不可触及前列腺癌男性中,靶向活检使约五分之一患者从有利中危升级为不利中危或更差疾病,对考虑主动监测或根治性治疗者有显著临床意义。
  • 作者认为随着靶向活检技术广泛采用,风险计算器必须使用这些靶向活检数据进行验证。

研究设计与样本

  • 回顾性分析,纳入2012年7月至2016年7月单家三级转诊中心连续107例经直肠超声引导系统非靶向穿刺确诊为Gleason 3+4的前列腺癌患者,随后行多参数MRI及MRI靶向经会阴前列腺穿刺活检以准确危险分层和定位。

主要发现

  • 患者平均(标准差)年龄67.0(8.0)岁,前列腺特异性抗原中位数(四分位距)6.2(4.7-9.6)ng/mL。
  • 107例中84例(78.5%)经直肠系统穿刺和经会阴MRI靶向穿刺均为Gleason 3+4。
  • 19例(17.8%)升级为Gleason 4+3,3例(3.0%)升级为Gleason 4+4,1例(1.0%)升级为Gleason 4+5,差异显著(P=0.0006)。
  • 23/107例(22%)基于靶向活检结果归为更高风险疾病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether patients with Gleason 3 + 4 cancer on transrectal biopsy are upgraded after undergoing transperineal magnetic resonance imaging (MRI)-targeted biopsy and whether this has implications for current clinical practice. PATIENTS AND METHODS: In this retrospective analysis we examined 107 consecutive patients presenting at a single tertiary referral centre (July 2012 to July 2016) with prostate cancer of Gleason score 3 + 4 on transrectal ultrasonography (TRUS)-guided systematic non-targeted biopsy who then underwent a multiparametric MRI followed by MRI-targeted transperineal prostate biopsy for accurate risk stratification and localization. RESULTS: The patients' mean (sd) age was 67.0 (8.0) years, and they had a median (interquartile range) PSA concentration of 6.2 (4.7-9.6) ng/mL. Of the 107 patients, 84 (78.5%) had Gleason 3 + 4 on both transrectal systematic biopsy and transperineal MRI-targeted biopsy. Nineteen patients (17.8%) were upgraded to Gleason 4 + 3, three patients (3.0%) to Gleason 4 + 4 and one patient (1.0%) to Gleason 4 + 5. These differences were significant (P = 0.0006). Likewise, 23/107 patients (22%) had higher-risk disease based on their targeted biopsies. CONCLUSION: The use of targeted biopsy in men with impalpable cancer, ultimately upgraded one in five patients from favourable-intermediate- to unfavourable-intermediate-risk disease or worse. This has significant clinical implications for men considering active surveillance or radical treatment. Our risk calculators must now be validated using these data from targeted biopsy as the technique becomes widely adopted.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Bass EJ, Orczyk C, Grey A, et al. Targeted biopsy of the prostate: does this result in improvement in detection of high-grade cancer or the occurrence of the Will Rogers phenomenon? BJU Int. 2019. PMID: 31081983. doi:10.1111/bju.14806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。